ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Practical Utility of Meropenem Therapeutic Drug Monitoring: A Systematic Review of Evidence for Clinical Application
Provisionally accepted
- Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background and Purpose: Therapeutic Drug Monitoring (TDM) is advocated to 2 / 27 optimize antibiotic therapy, yet its efficacy remains debated. This systematic review and meta-analysis evaluates TDM's impact on meropenem therapy, focusing on treatment efficacy, bacterial clearance, and changes in biomarkers (C-reactive protein (CRP) levels, procalcitonin (PCT) levels, white blood cell (WBC) count, neutrophil ratios). Methods: A systematic search was conducted across multiple databases, including PubMed, Embase, Web of Science, the Cochrane Library, and CNKI. Eligible studies comparing TDM with non-TDM approaches for meropenem were identified according to predefined inclusion and exclusion criteria. Pooled analyses were conducted using fixed-effects or random-effects models, selected based on the degree of heterogeneity among studies. Results: A total of nine studies comprising 834 patients met the inclusion criteria and were included in the analysis. The study populations primarily consisted of adult and elderly patients with moderate to severe infections, including respiratory tract, urinary tract, and bloodstream infections. TDM significantly improved treatment efficacy (RR = 1.19; 95% CI: 1.10-1.28) and bacterial clearance rates (RR = 1.29; 95% CI: 1.12-1.48). CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79-27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. Adverse reactions showed a non-significant reduction (RR = 0.65; 95% CI: 0.38-1.11). Low heterogeneity across studies supports the robustness of these findings. Conclusions: TDM enhances treatment efficacy and bacterial clearance in meropenem therapy, but its impact on adverse reactions and certain biomarkers remains uncertain. Further research is needed to clarify TDM's clinical utility and limitations.
Keywords: Therapeutic drug monitoring, Meropenem, clinical outcomes, AntibioticTherapy, Meta-analysis
Received: 15 Oct 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Zhao, Liu, Li, Liu, Sun, Zhang and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Miao Yan, yanmiao@csu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.